AR035854A1 - Compuestos derivados de piridopirimidina y naftiridina, su uso, un procedimiento para prepararlos, una composicion que los comprende, compuestos intermediarios y un proceso para preparar un compuesto sulfuro - Google Patents
Compuestos derivados de piridopirimidina y naftiridina, su uso, un procedimiento para prepararlos, una composicion que los comprende, compuestos intermediarios y un proceso para preparar un compuesto sulfuroInfo
- Publication number
- AR035854A1 AR035854A1 ARP020100430A ARP020100430A AR035854A1 AR 035854 A1 AR035854 A1 AR 035854A1 AR P020100430 A ARP020100430 A AR P020100430A AR P020100430 A ARP020100430 A AR P020100430A AR 035854 A1 AR035854 A1 AR 035854A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- cycloalkyl
- aryl
- cycloalkylalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 150000003464 sulfur compounds Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 25
- 229910052739 hydrogen Inorganic materials 0.000 abstract 18
- 239000001257 hydrogen Substances 0.000 abstract 18
- 150000002431 hydrogen Chemical group 0.000 abstract 11
- 125000003118 aryl group Chemical group 0.000 abstract 9
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 9
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 8
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 7
- -1 monoalkylamino Chemical group 0.000 abstract 6
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 5
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 208000035475 disorder Diseases 0.000 abstract 4
- 125000001188 haloalkyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000002252 acyl group Chemical group 0.000 abstract 3
- 125000004966 cyanoalkyl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 3
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 125000001769 aryl amino group Chemical group 0.000 abstract 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 abstract 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 abstract 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26837501P | 2001-02-12 | 2001-02-12 | |
| US33465401P | 2001-11-30 | 2001-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035854A1 true AR035854A1 (es) | 2004-07-21 |
Family
ID=26953040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100430A AR035854A1 (es) | 2001-02-12 | 2002-02-11 | Compuestos derivados de piridopirimidina y naftiridina, su uso, un procedimiento para prepararlos, una composicion que los comprende, compuestos intermediarios y un proceso para preparar un compuesto sulfuro |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US6696566B2 (https=) |
| EP (1) | EP1361880B1 (https=) |
| JP (1) | JP4064818B2 (https=) |
| KR (1) | KR100639772B1 (https=) |
| CN (1) | CN100376571C (https=) |
| AR (1) | AR035854A1 (https=) |
| AT (1) | ATE305303T1 (https=) |
| AU (1) | AU2002256615B2 (https=) |
| BR (1) | BRPI0207172B8 (https=) |
| CA (1) | CA2434834C (https=) |
| CZ (1) | CZ20032416A3 (https=) |
| DE (1) | DE60206363T2 (https=) |
| DK (1) | DK1361880T3 (https=) |
| ES (1) | ES2249574T3 (https=) |
| HR (1) | HRP20030624B1 (https=) |
| HU (1) | HU229604B1 (https=) |
| IL (2) | IL156872A0 (https=) |
| JO (1) | JO2410B1 (https=) |
| MA (1) | MA26993A1 (https=) |
| MX (1) | MXPA03007166A (https=) |
| MY (1) | MY131518A (https=) |
| NO (1) | NO326133B1 (https=) |
| NZ (1) | NZ526961A (https=) |
| PA (1) | PA8539201A1 (https=) |
| PE (1) | PE20020976A1 (https=) |
| PL (1) | PL366918A1 (https=) |
| RU (1) | RU2269527C2 (https=) |
| SK (1) | SK11322003A3 (https=) |
| WO (1) | WO2002064594A2 (https=) |
| YU (1) | YU63703A (https=) |
| ZA (1) | ZA200305938B (https=) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7053070B2 (en) * | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| DE60206363T2 (de) | 2001-02-12 | 2006-07-06 | F. Hoffmann-La Roche Ag | 6-substituierte pyridopyrimidine |
| ES2251677T3 (es) * | 2002-01-22 | 2006-05-01 | Warner-Lambert Company Llc | 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas. |
| EP1492790A1 (en) | 2002-04-03 | 2005-01-05 | F. Hoffmann-La Roche Ag | Imidazo fused compounds |
| CA2492112A1 (en) * | 2002-08-06 | 2004-02-19 | F. Hoffmann-La Roche Ag | 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors |
| EP2181704B1 (en) | 2002-12-30 | 2015-05-06 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| CA2517256C (en) * | 2003-02-26 | 2013-04-30 | Sugen, Inc. | Aminoheteroaryl compounds as protein kinase inhibitors |
| AU2004229163A1 (en) * | 2003-04-16 | 2004-10-28 | F. Hoffmann-La Roche Ag | (6-(phenoxy)-pyrido`3,4-d! PYRIMIDIN-2-YL)-AMINE DERIVATIVES AS P38 KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORYY CONDITIONS SUCH AS RHEUMATOIS ARTRITIS |
| WO2005047284A1 (en) * | 2003-11-13 | 2005-05-26 | F. Hoffmann-La Roche Ag | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones |
| EP1831215A1 (en) * | 2004-11-23 | 2007-09-12 | Ranbaxy Laboratories Limited | Pyrido[2,3-d]pyrimidines as anti-inflamatory agents |
| US20060142312A1 (en) * | 2004-12-23 | 2006-06-29 | Pfizer Inc | C6-aryl and heteroaryl substituted pyrido[2,3-D] pyrimidin-7-ones |
| EP1846403A1 (en) * | 2005-02-02 | 2007-10-24 | Ranbaxy Laboratories Limited | Azabicyclo derivatives as anti-inflammatory agents |
| MX2007013595A (es) * | 2005-05-04 | 2008-01-24 | Renovis Inc | Compuestos heterociclicos fusionados y composiciones y usos de estos. |
| WO2007009911A1 (en) * | 2005-07-21 | 2007-01-25 | F. Hoffmann-La Roche Ag | PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS |
| ATE482958T1 (de) * | 2005-08-09 | 2010-10-15 | Irm Llc | Verbindungen und zusammensetzungen als proteinkinaseinhibitoren |
| WO2007022946A1 (de) | 2005-08-21 | 2007-03-01 | Abbott Gmbh & Co. Kg | Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
| JO2783B1 (en) * | 2005-09-30 | 2014-03-15 | نوفارتيس ايه جي | Compounds 2-Amino-7, 8-dihydro-6H-Bayredo (3,4-D) Pyrimidine-5-Ones |
| CN101454319B (zh) * | 2006-05-26 | 2012-06-27 | 富山化学工业株式会社 | 新杂环化合物或其盐及其中间体 |
| WO2008150260A1 (en) * | 2007-06-06 | 2008-12-11 | Gpc Biotech, Inc. | 8-oxy-2-aminopyrido (2, 3-d) pyrimidin-7-one derivatives as kinase inhibitors and anticancer agents |
| WO2008078249A1 (en) * | 2006-12-21 | 2008-07-03 | Ranbaxy Laboratories Limited | Anti-inflammatory agents |
| US8022085B2 (en) | 2007-05-07 | 2011-09-20 | Amgen Inc. | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as P38 modulators and methods of use thereof |
| CA2690327A1 (en) | 2007-06-15 | 2008-12-18 | Thomas P. Cleary | A novel process for the preparation of 3-amino-pentan-1,5-diol |
| US8367671B2 (en) | 2008-03-21 | 2013-02-05 | Amgen Inc. | Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents |
| EP2112150B1 (en) | 2008-04-22 | 2013-10-16 | Forma Therapeutics, Inc. | Improved raf inhibitors |
| JP2012505927A (ja) * | 2008-10-22 | 2012-03-08 | エフ．ホフマン−ラ ロシュ アーゲー | Ｊｎｋのピリミジニルピリドン阻害剤 |
| WO2010071846A2 (en) | 2008-12-19 | 2010-06-24 | Afraxis, Inc. | Compounds for treating neuropsychiatric conditions |
| JP2013507395A (ja) | 2009-10-09 | 2013-03-04 | アフラクシス・インコーポレイテッド | Ｃｎｓ障害治療用の８−エチル−６−（アリール）ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オン |
| US8889696B2 (en) * | 2009-12-18 | 2014-11-18 | Temple University—Of the Commonwealth System of Higher Education | Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof |
| KR20170032244A (ko) | 2014-07-26 | 2017-03-22 | 선샤인 레이크 파르마 컴퍼니 리미티드 | Cdk 저해제로서 2-아미노-피리도[2,3-d]피리미딘-7(8h)-온 유도체 및 그 용도 |
| ES2866883T3 (es) * | 2016-06-08 | 2021-10-20 | Support Venture Gmbh | Combinaciones farmacéuticas para el tratamiento del cáncer |
| CN109803968A (zh) | 2016-08-15 | 2019-05-24 | 辉瑞公司 | 吡啶并嘧啶酮cdk2/4/6抑制剂 |
| CA3033887A1 (en) * | 2016-08-17 | 2018-02-22 | Support-Venture Gmbh | Method of preventing or treating hearing loss |
| US11117858B2 (en) | 2017-01-11 | 2021-09-14 | The General Hospital Corporation | Voltage gated sodium channel imaging agents |
| CN110636840A (zh) | 2017-04-04 | 2019-12-31 | 斯特里金股份公司 | 预防或治疗眼科疾病的方法 |
| CN111032655B (zh) * | 2017-08-31 | 2022-09-02 | 达纳-法伯癌症研究所股份有限公司 | Egfr和/或her2抑制剂和使用方法 |
| WO2019071147A1 (en) | 2017-10-05 | 2019-04-11 | Fulcrum Therapeutics, Inc. | INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| WO2020006210A1 (en) * | 2018-06-27 | 2020-01-02 | Tufts Medical Center, Inc. | Pyridopyrimidine compounds and methods of their use |
| SG11202012775SA (en) | 2018-07-13 | 2021-02-25 | Kinarus Ag | Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases |
| TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| WO2022034031A1 (en) | 2020-08-11 | 2022-02-17 | Kinarus Ag | Methods of preventing or treating covid-19 and related viral diseases or disorders |
| CN120247910A (zh) * | 2025-04-01 | 2025-07-04 | 赣南师范大学 | 一种杂环类化合物及其制备方法、应用和防治肿瘤的药物组合物 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4215216A (en) | 1979-04-18 | 1980-07-29 | American Home Products Corporation | 7,8-Dihydro-2,5,8-trisubstituted-7-oxo-pyrido[2,3-d]pyrimidine-6-carboxylic acid derivatives |
| US5037826A (en) | 1986-10-15 | 1991-08-06 | Schering Corporation | 1-substituted naphthyridine and pyridopyrazine derivatives |
| GB8702758D0 (en) * | 1987-02-06 | 1987-03-11 | Wellcome Found | Treatment of disease |
| AU598093B2 (en) | 1987-02-07 | 1990-06-14 | Wellcome Foundation Limited, The | Pyridopyrimidines, methods for their preparation and pharmaceutical formulations thereof |
| ATE194985T1 (de) * | 1990-11-06 | 2000-08-15 | Yamanouchi Pharma Co Ltd | Kondensiertes pyrazinderivat |
| WO1993017682A1 (en) | 1992-03-04 | 1993-09-16 | Abbott Laboratories | Angiotensin ii receptor antagonists |
| TW299333B (https=) * | 1992-12-29 | 1997-03-01 | Takeda Pharm Industry Co Ltd | |
| HUT76853A (en) * | 1994-11-14 | 1997-12-29 | Warner Lambert Co | 6-aryl pyrido[2,3-d]pyrimidines and naphthyridines for inhibiting protein tyrosine kinase mediated cellular proliferation and pharmaceutical compositions containing the same |
| IL115256A0 (en) * | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
| US5620981A (en) | 1995-05-03 | 1997-04-15 | Warner-Lambert Company | Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation |
| IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
| US6147080A (en) * | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| ES2301194T3 (es) | 1997-02-05 | 2008-06-16 | Warner-Lambert Company Llc | Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular. |
| US5945422A (en) | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
| AU7108398A (en) | 1997-04-16 | 1998-11-11 | Abbott Laboratories | 5,7-disubstituted 4-aminopyrido{2,3-d}pyrimidine compounds and their use as adenosine kinase inhibitors |
| TR199902550T2 (xx) | 1997-04-16 | 2000-04-21 | Abbott Laboratories | 5, 6, 7-Tris�bstit�e -4-aminopirido $2,3-D] pirimidin bile�ikleri. |
| TW458977B (en) * | 1997-04-16 | 2001-10-11 | Abbott Lab | 6,7-disubstituted-4-aminopyrido[2,3-D] pyrimidine compounds |
| AU763839B2 (en) | 1998-05-26 | 2003-07-31 | Warner-Lambert Company | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation |
| BR9911365A (pt) | 1998-06-19 | 2001-03-13 | Pfizer Prod Inc | Compostos pirrolo[2,3-d]pirimidina |
| EP1078923B1 (en) | 1999-08-02 | 2006-03-08 | F. Hoffmann-La Roche Ag | Process for the preparation of benzothiophene derivatives |
| US7053070B2 (en) * | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
| PL358271A1 (pl) * | 2000-03-06 | 2004-08-09 | Warner-Lambert Company | 5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny |
| US6518276B2 (en) * | 2000-08-31 | 2003-02-11 | Syntex (U.S.A.) Llc | 7-oxo-pyridopyrimidines (II) |
| DE60206363T2 (de) | 2001-02-12 | 2006-07-06 | F. Hoffmann-La Roche Ag | 6-substituierte pyridopyrimidine |
| ES2251677T3 (es) * | 2002-01-22 | 2006-05-01 | Warner-Lambert Company Llc | 2-(piridin-2-ilamino)-pirido(2,3-d)pirimidin-7-onas. |
-
2002
- 2002-02-04 DE DE60206363T patent/DE60206363T2/de not_active Expired - Lifetime
- 2002-02-04 HR HR20030624A patent/HRP20030624B1/xx not_active IP Right Cessation
- 2002-02-04 ES ES02726103T patent/ES2249574T3/es not_active Expired - Lifetime
- 2002-02-04 EP EP02726103A patent/EP1361880B1/en not_active Expired - Lifetime
- 2002-02-04 MX MXPA03007166A patent/MXPA03007166A/es active IP Right Grant
- 2002-02-04 BR BRPI0207172-0 patent/BRPI0207172B8/pt not_active IP Right Cessation
- 2002-02-04 AU AU2002256615A patent/AU2002256615B2/en not_active Expired
- 2002-02-04 PL PL02366918A patent/PL366918A1/xx not_active Application Discontinuation
- 2002-02-04 JP JP2002564525A patent/JP4064818B2/ja not_active Expired - Lifetime
- 2002-02-04 YU YU63703A patent/YU63703A/sh unknown
- 2002-02-04 HU HU0303458A patent/HU229604B1/hu unknown
- 2002-02-04 WO PCT/EP2002/001106 patent/WO2002064594A2/en not_active Ceased
- 2002-02-04 CA CA2434834A patent/CA2434834C/en not_active Expired - Lifetime
- 2002-02-04 AT AT02726103T patent/ATE305303T1/de active
- 2002-02-04 CN CNB028048342A patent/CN100376571C/zh not_active Expired - Lifetime
- 2002-02-04 RU RU2003125887/04A patent/RU2269527C2/ru not_active IP Right Cessation
- 2002-02-04 SK SK11322003A patent/SK11322003A3/sk unknown
- 2002-02-04 KR KR1020037010562A patent/KR100639772B1/ko not_active Expired - Lifetime
- 2002-02-04 CZ CZ20032416A patent/CZ20032416A3/cs unknown
- 2002-02-04 IL IL15687202A patent/IL156872A0/xx unknown
- 2002-02-04 NZ NZ526961A patent/NZ526961A/en unknown
- 2002-02-04 DK DK02726103T patent/DK1361880T3/da active
- 2002-02-06 JO JO200212A patent/JO2410B1/en active
- 2002-02-08 PE PE2002000097A patent/PE20020976A1/es not_active Application Discontinuation
- 2002-02-08 PA PA20028539201A patent/PA8539201A1/es unknown
- 2002-02-11 AR ARP020100430A patent/AR035854A1/es unknown
- 2002-02-11 MY MYPI20020491A patent/MY131518A/en unknown
- 2002-02-11 US US10/073,845 patent/US6696566B2/en not_active Expired - Lifetime
-
2003
- 2003-07-10 IL IL156872A patent/IL156872A/en unknown
- 2003-07-31 ZA ZA2003/05938A patent/ZA200305938B/en unknown
- 2003-08-11 MA MA27273A patent/MA26993A1/fr unknown
- 2003-08-11 NO NO20033540A patent/NO326133B1/no not_active IP Right Cessation
- 2003-11-25 US US10/722,703 patent/US7169794B2/en not_active Expired - Lifetime
-
2007
- 2007-01-09 US US11/651,302 patent/US7449581B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035854A1 (es) | Compuestos derivados de piridopirimidina y naftiridina, su uso, un procedimiento para prepararlos, una composicion que los comprende, compuestos intermediarios y un proceso para preparar un compuesto sulfuro | |
| AR032621A1 (es) | Compuestos derivados de tiofeno, metodo para su preparacion, composicion farmaceutica y uso en la fabricacion de medicamentos | |
| HUP0100950A2 (hu) | Ciklusos aminovegyületek, alkalmazásuk gyógyászati készítmények előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
| CO5251381A1 (es) | Derivados de adamantano, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR081331A1 (es) | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos | |
| AR055198A1 (es) | Formulaciones farmaceuticas y metodos de tratamiento que las utilizan | |
| AR039933A1 (es) | Indoles sustituidos para tratamiento de desordenes respiratorios | |
| AR058557A1 (es) | Derivados de pirimidina, procesos de preparacion, y composiciones farmaceuticas que los comprenden | |
| DE69406649D1 (de) | N-alkyl-2-substituierte atp-analoge | |
| AR040498A1 (es) | Indoles sustituidos utiles para el tratamiento de enfermedades respiratorias | |
| AR081626A1 (es) | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| AR015512A1 (es) | Derivados ciclicos n-acilo amina, un procedimiento para su preparacion, un intermediario y una composicion farmaceutica | |
| CO5640152A2 (es) | Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c | |
| AR040031A1 (es) | Compuestos de pirazol-pirimidina anilina utiles como inhibidores de cinasa y composiciones farmaceuticas que los contienen | |
| NO20060975L (no) | 1-Benzoyl-piperazinderivater som glycin gjenopptaksinhibitorer for behandling av psykoser | |
| ES2092651T3 (es) | Derivados heterociclicos diazotados n-sustituidos por un grupo bifenilmetilo, su preparacion, las composiciones farmaceuticas que los contienen. | |
| HRP20080113T3 (hr) | Supstituirani piridinilni i pirimidinilni derivati kao modulatori metabolizma i liječenje bolesti koje su s tim povezane | |
| AR069796A1 (es) | Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| RU2005137032A (ru) | Применение оксазолидинон-хинолиновых гибридных антибиотиков для лечения сибирской язвы и других инфекций | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| ATE463483T1 (de) | 6-substituierte isochinolinderivate als rock-1- inhibitoren | |
| CO5650164A2 (es) | Hetrociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6 | |
| AR064414A1 (es) | Derivados de 1-azoniabiciclo[2, 2, 2]octano y 1-azabiciclo[2, 2, 2]oct-3-ilo, un proceso para su preparacion, una composicion farmaceutica que los comprende, procedimiento de obtencion de la misma, su uso en la elaboracion de un medicamento para el tratamiento de epoc y un producto farmaceutico que | |
| AR045155A1 (es) | Derivados de 6-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |